SC
EWTX icon

SummitTX Capital’s Edgewise Therapeutics EWTX Stock Holding History

SummitTX Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,782
Closed -$337K – 778
2025
Q3 		$337K Sell
20,782
-598
-3% -$8.48K 0.01% 607
2025
Q2 		$280K Buy
21,380
+11,716
+121% +$169K 0.01% 634
2025
Q1 		$213K Buy
+9,664
New +$254K 0.01% 724

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SummitTX Capital's EWTX Position: Q4 2025 in Review

SummitTX Capital sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 20,782 shares — an estimated $337K sold.

SummitTX Capital first reported a position in EWTX in Q1 2025 and held it in 3 quarters. The position peaked at $337K in Q3 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • SummitTX Capital reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SummitTX Capital sold 20,782 Edgewise Therapeutics shares in Q4 2025, an estimated $337K.
  • SummitTX Capital first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 3 quarters.
  • SummitTX Capital's Edgewise Therapeutics position peaked at $337K in Q3 2025.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.